Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Oncology

Pharmacology/Therapy

Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164

Journal of Clinical Oncology | Jan 06, 2020 Pharmacology/Therapy

Pd-1 blockade in advanced adrenocortical carcinoma

Journal of Clinical Oncology | Jan 06, 2020 Pharmacology/Therapy

Breast cancer characteristics and survival among users vs nonusers of raloxifene

Cancer Prevention Research | Jan 06, 2020 Pharmacology/Therapy

Final progression-free survival results from the J-ALEX study of alectinib vs crizotinib in ALK-positive non-small-cell lung cancer

Lung Cancer | Jan 06, 2020 Pharmacology/Therapy

A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

BMC Cancer | Jan 06, 2020 Pharmacology/Therapy

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab vs trifluridine/tipiracil monotherapy for metastatic colorectal cancer

BMC Cancer | Jan 06, 2020 Pharmacology/Therapy

Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status

Cancer Medicine | Jan 06, 2020 Pharmacology/Therapy

Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

New England Journal of Medicine | Dec 26, 2019 Pharmacology/Therapy

Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer

New England Journal of Medicine | Dec 26, 2019 Pharmacology/Therapy

Niraparib in patients with newly diagnosed advanced ovarian cancer

New England Journal of Medicine | Dec 26, 2019 Pharmacology/Therapy

« Prev 1 … 101 102 103 104 105 … 375 Next »

Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164

Pd-1 blockade in advanced adrenocortical carcinoma

Breast cancer characteristics and survival among users vs nonusers of raloxifene

Final progression-free survival results from the J-ALEX study of alectinib vs crizotinib in ALK-positive non-small-cell lung cancer

A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab vs trifluridine/tipiracil monotherapy for metastatic colorectal cancer

Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status

Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer

Niraparib in patients with newly diagnosed advanced ovarian cancer

MD Clip on Diabetes & Urinary ACR: Detecting Kidney Damage Early with Dr Saraogi

Article: How to Diagnose and Differentiate Common Causes of Sudden Vision Loss

Article: A Review on Fluoride Effects on Thyroid Function

30-year-old athlete suffers fatal heart attack—could you have seen this coming?

New research aims to transform treatments of aggressive blood cancer

Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164

Pd-1 blockade in advanced adrenocortical carcinoma

Breast cancer characteristics and survival among users vs nonusers of raloxifene

Final progression-free survival results from the J-ALEX study of alectinib vs crizotinib in ALK-positive non-small-cell lung cancer

A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab vs trifluridine/tipiracil monotherapy for metastatic colorectal cancer

Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status

Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer

Niraparib in patients with newly diagnosed advanced ovarian cancer

MD Clip on Diabetes & Urinary ACR: Detecting Kidney Damage Early with Dr Saraogi

Article: How to Diagnose and Differentiate Common Causes of Sudden Vision Loss

Article: A Review on Fluoride Effects on Thyroid Function

30-year-old athlete suffers fatal heart attack—could you have seen this coming?

New research aims to transform treatments of aggressive blood cancer

Select Specialty

Select Topic